IRON - Disc Medicine, Inc.
IEX Last Trade
64.35
0.190 0.295%
Share volume: 3,608
Last Updated: Fri 27 Dec 2024 08:30:40 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$64.16
0.19
0.30%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
2.71%
1 Month
1.53%
3 Months
30.90%
6 Months
47.78%
1 Year
13.14%
2 Year
4,754.81%
Key data
Stock price
$64.35
DAY RANGE
$63.67 - $65.20
52 WEEK RANGE
$27.04 - $77.60
52 WEEK CHANGE
$13.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Georges Gemayel
Region: US
Website: geminitherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: geminitherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Gemini Therapeutics, Inc. engages in developing therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) Its lead candidate is GEM103, a recombinant form of the human complement factor H protein. The company also develops GEM307 for treatment of systemic diseases.
Recent news